{"id":2082,"date":"2025-10-29T10:57:18","date_gmt":"2025-10-29T10:57:18","guid":{"rendered":"https:\/\/www.strategymrc.com\/blog\/?p=2082"},"modified":"2025-10-29T10:57:19","modified_gmt":"2025-10-29T10:57:19","slug":"chinas-mazdutide-surpasses-semaglutide","status":"publish","type":"post","link":"https:\/\/www.strategymrc.com\/blog\/chinas-mazdutide-surpasses-semaglutide\/","title":{"rendered":"China\u2019s Mazdutide Surpasses Semaglutide|  A New Era for the Global Diabetes Drugs Market"},"content":{"rendered":"\n<p>The global race to dominate the diabetes drug market has taken a dramatic turn.<br>In a groundbreaking head-to-head clinical trial, <strong>China\u2019s Mazdutide<\/strong> \u2014 a novel GLP-1\/GIP dual agonist \u2014 has <strong>outperformed Novo Nordisk\u2019s Semaglutide<\/strong>, the active ingredient behind blockbuster brands <em>Ozempic<\/em> and <em>Wegovy<\/em>.<\/p>\n\n\n\n<p>This isn\u2019t just another clinical milestone \u2014 it marks a <strong>strategic power shift<\/strong> in global pharmaceutical innovation, with China emerging as a serious contender in the rapidly expanding diabetes therapeutics market.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" style=\"font-size:24px\"><strong>What is Mazdutide?<\/strong><\/h2>\n\n\n\n<p>Mazdutide, developed by <strong>Innovent Biologics<\/strong>, is a <strong>dual-receptor agonist<\/strong> that targets both <strong>GLP-1 (glucagon-like peptide-1)<\/strong> and <strong>GIP (glucose-dependent insulinotropic polypeptide)<\/strong> receptors.<br>This dual mechanism enhances insulin secretion, improves blood sugar control, and promotes weight reduction \u2014 offering a <strong>more comprehensive metabolic benefit<\/strong> than single-pathway drugs.<\/p>\n\n\n\n<p>In recent trials, Mazdutide not only matched but <strong>exceeded Semaglutide\u2019s efficacy<\/strong> in:<\/p>\n\n\n\n<ul>\n<li>Lowering HbA1c levels (blood sugar control marker)<\/li>\n\n\n\n<li>Achieving higher weight loss percentages<\/li>\n\n\n\n<li>Showing improved safety and tolerance profile<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" style=\"font-size:24px\"><strong>Clinical Breakthrough: Mazdutide vs. Semaglutide<\/strong><\/h2>\n\n\n\n<p>According to Innovent\u2019s Phase III clinical study:<\/p>\n\n\n\n<ul>\n<li>Mazdutide achieved a <strong>greater reduction in HbA1c<\/strong> over 24 weeks.<\/li>\n\n\n\n<li>Patients experienced an <strong>average weight loss exceeding 12%<\/strong>, compared to 9\u201310% with Semaglutide.<\/li>\n\n\n\n<li>The therapy demonstrated <strong>superior metabolic control<\/strong> with fewer gastrointestinal side effects.<\/li>\n<\/ul>\n\n\n\n<p>This success positions Mazdutide as a <strong>next-generation therapy<\/strong> capable of transforming diabetes care and obesity management \u2014 two of the fastest-growing global health challenges.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" style=\"font-size:24px\"><strong>Market Implications: The Global Diabetes Drugs Boom<\/strong><\/h2>\n\n\n\n<p>The <strong>Global Diabetes Drugs Market<\/strong> is entering a new growth phase, fueled by rapid advancements in <strong>GLP-1 therapies<\/strong>, personalized medicine, and digital health integration.<\/p>\n\n\n\n<p>According to Stratistics MRC:<\/p>\n\n\n\n<ul>\n<li><strong>Market Size (2024):<\/strong> USD 85.6 Billion<\/li>\n\n\n\n<li><strong>Forecast (2032):<\/strong> USD 137.4 Billion<\/li>\n\n\n\n<li><strong>CAGR (2024\u20132032):<\/strong> 6.2%<\/li>\n<\/ul>\n\n\n\n<p>The <strong>GLP-1 drug class<\/strong> (which includes Semaglutide, Liraglutide, and now Mazdutide) represents <strong>the fastest-growing therapeutic segment<\/strong>, expected to surpass <strong>USD 48 Billion by 2032<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" style=\"font-size:24px\"><strong>Why China\u2019s Entry Changes Everything<\/strong><\/h2>\n\n\n\n<p>China\u2019s rise in biopharma innovation is accelerating \u2014 backed by government incentives, global R&amp;D partnerships, and strong domestic demand.<br>Here\u2019s why Mazdutide\u2019s success could reshape global competition:<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" style=\"font-size:20px\"><strong>1. Localization and Affordability<\/strong><\/h3>\n\n\n\n<p>Mazdutide is <strong>locally manufactured<\/strong>, allowing for <strong>lower production and distribution costs<\/strong> \u2014 making advanced diabetes care more affordable for Asia\u2019s vast patient base.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" style=\"font-size:20px\"><strong>2. Strong R&amp;D Ecosystem<\/strong><\/h3>\n\n\n\n<p>China\u2019s pharmaceutical ecosystem is rapidly maturing, with AI-driven research, biotech incubators, and cross-border clinical collaborations fueling faster drug development cycles.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" style=\"font-size:20px\"><strong>3. Global Export Potential<\/strong><\/h3>\n\n\n\n<p>With regulatory pathways opening between <strong>China, Europe, and the U.S.<\/strong>, Mazdutide could soon enter international markets \u2014 challenging established GLP-1 leaders like Novo Nordisk and Eli Lilly.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" style=\"font-size:24px\"><strong>Challenges Ahead<\/strong><\/h2>\n\n\n\n<p>Despite promising data, Mazdutide\u2019s global rollout faces hurdles:<\/p>\n\n\n\n<ul>\n<li>Regulatory approvals outside China will require extensive validation.<\/li>\n\n\n\n<li>Large-scale manufacturing and long-term safety studies are still underway.<\/li>\n\n\n\n<li>Competition from <strong>emerging peptide-based and oral GLP-1 alternatives<\/strong> remains strong.<\/li>\n<\/ul>\n\n\n\n<p>However, its <strong>cost advantage, innovative mechanism, and strong early data<\/strong> give it a clear competitive edge.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" style=\"font-size:24px\"><strong>The Bigger Picture: Redefining the Future of Diabetes Care<\/strong><\/h2>\n\n\n\n<p>The success of Mazdutide underscores a broader trend \u2014 the <strong>globalization of medical innovation<\/strong>.<br>No longer confined to Western pharmaceutical giants, the future of diabetes care is being shaped by <strong>a diverse set of players<\/strong> leveraging technology, biology, and local healthcare infrastructure.<\/p>\n\n\n\n<p>As global diabetes prevalence is expected to reach <strong>643 million adults by 2030<\/strong>, the need for <strong>affordable, effective, and scalable therapies<\/strong> has never been greater.<\/p>\n\n\n\n<p>Mazdutide\u2019s triumph over Semaglutide isn\u2019t just a win for China \u2014 it\u2019s a signal that the global diabetes treatment landscape is <strong>on the brink of transformation<\/strong>.<br>With biotechnology breakthroughs emerging across continents, the next decade will define <strong>who leads the future of metabolic medicine<\/strong> \u2014 and who adapts fastest to innovation.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><\/h2>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><strong><a href=\"https:\/\/www.strategymrc.com\/report\/diabetes-drugs-market\">Explore the full Global Diabetes Drugs Market Forecast (2024\u20132032)<\/a><\/strong><br>Gain insights into drug pipelines, regional growth, GLP-1 innovations, and strategic opportunities shaping the next decade of diabetes care.<\/p>\n<\/blockquote>\n","protected":false},"excerpt":{"rendered":"<p>The global race to dominate the diabetes drug market has taken a dramatic turn.In a groundbreaking head-to-head clinical trial, China\u2019s Mazdutide \u2014 a novel GLP-1\/GIP dual agonist \u2014 has outperformed Novo Nordisk\u2019s Semaglutide, the active ingredient behind blockbuster brands Ozempic and Wegovy. This isn\u2019t just another clinical milestone \u2014 it marks a strategic power shift [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[1],"tags":[],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v19.6 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>China\u2019s Mazdutide Surpasses Semaglutide | A New Era for the Global Diabetes Drugs Market<\/title>\n<meta name=\"description\" content=\"Discover how China\u2019s Mazdutide outperformed Novo Nordisk\u2019s Semaglutide in clinical trials \u2014 reshaping the $85B global diabetes drugs market with breakthrough GLP-1 innovation.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.strategymrc.com\/blog\/chinas-mazdutide-surpasses-semaglutide\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"China\u2019s Mazdutide Surpasses Semaglutide | A New Era for the Global Diabetes Drugs Market\" \/>\n<meta property=\"og:description\" content=\"Discover how China\u2019s Mazdutide outperformed Novo Nordisk\u2019s Semaglutide in clinical trials \u2014 reshaping the $85B global diabetes drugs market with breakthrough GLP-1 innovation.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.strategymrc.com\/blog\/chinas-mazdutide-surpasses-semaglutide\/\" \/>\n<meta property=\"og:site_name\" content=\"Stratistics MRC\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-29T10:57:18+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-10-29T10:57:19+00:00\" \/>\n<meta name=\"author\" content=\"Akash\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Akash\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.strategymrc.com\/blog\/chinas-mazdutide-surpasses-semaglutide\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.strategymrc.com\/blog\/chinas-mazdutide-surpasses-semaglutide\/\"},\"author\":{\"name\":\"Akash\",\"@id\":\"https:\/\/www.strategymrc.com\/blog\/#\/schema\/person\/599a89cba7fe0a22404cf43445567bdf\"},\"headline\":\"China\u2019s Mazdutide Surpasses Semaglutide| A New Era for the Global Diabetes Drugs Market\",\"datePublished\":\"2025-10-29T10:57:18+00:00\",\"dateModified\":\"2025-10-29T10:57:19+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.strategymrc.com\/blog\/chinas-mazdutide-surpasses-semaglutide\/\"},\"wordCount\":626,\"publisher\":{\"@id\":\"https:\/\/www.strategymrc.com\/blog\/#organization\"},\"articleSection\":[\"Blog\"],\"inLanguage\":\"en\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.strategymrc.com\/blog\/chinas-mazdutide-surpasses-semaglutide\/\",\"url\":\"https:\/\/www.strategymrc.com\/blog\/chinas-mazdutide-surpasses-semaglutide\/\",\"name\":\"China\u2019s Mazdutide Surpasses Semaglutide | A New Era for the Global Diabetes Drugs Market\",\"isPartOf\":{\"@id\":\"https:\/\/www.strategymrc.com\/blog\/#website\"},\"datePublished\":\"2025-10-29T10:57:18+00:00\",\"dateModified\":\"2025-10-29T10:57:19+00:00\",\"description\":\"Discover how China\u2019s Mazdutide outperformed Novo Nordisk\u2019s Semaglutide in clinical trials \u2014 reshaping the $85B global diabetes drugs market with breakthrough GLP-1 innovation.\",\"breadcrumb\":{\"@id\":\"https:\/\/www.strategymrc.com\/blog\/chinas-mazdutide-surpasses-semaglutide\/#breadcrumb\"},\"inLanguage\":\"en\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.strategymrc.com\/blog\/chinas-mazdutide-surpasses-semaglutide\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.strategymrc.com\/blog\/chinas-mazdutide-surpasses-semaglutide\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.strategymrc.com\/blog\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"China\u2019s Mazdutide Surpasses Semaglutide| A New Era for the Global Diabetes Drugs Market\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.strategymrc.com\/blog\/#website\",\"url\":\"https:\/\/www.strategymrc.com\/blog\/\",\"name\":\"Stratistics MRC\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.strategymrc.com\/blog\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.strategymrc.com\/blog\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.strategymrc.com\/blog\/#organization\",\"name\":\"Stratistics MRC\",\"url\":\"https:\/\/www.strategymrc.com\/blog\/\",\"sameAs\":[],\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en\",\"@id\":\"https:\/\/www.strategymrc.com\/blog\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.strategymrc.com\/blog\/wp-content\/uploads\/2022\/08\/smrc-logo-sm.png\",\"contentUrl\":\"https:\/\/www.strategymrc.com\/blog\/wp-content\/uploads\/2022\/08\/smrc-logo-sm.png\",\"width\":150,\"height\":38,\"caption\":\"Stratistics MRC\"},\"image\":{\"@id\":\"https:\/\/www.strategymrc.com\/blog\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.strategymrc.com\/blog\/#\/schema\/person\/599a89cba7fe0a22404cf43445567bdf\",\"name\":\"Akash\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en\",\"@id\":\"https:\/\/www.strategymrc.com\/blog\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/ef8cf3725231b15449bb719267bbb94f?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/ef8cf3725231b15449bb719267bbb94f?s=96&d=mm&r=g\",\"caption\":\"Akash\"},\"url\":\"https:\/\/www.strategymrc.com\/blog\/author\/akash\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"China\u2019s Mazdutide Surpasses Semaglutide | A New Era for the Global Diabetes Drugs Market","description":"Discover how China\u2019s Mazdutide outperformed Novo Nordisk\u2019s Semaglutide in clinical trials \u2014 reshaping the $85B global diabetes drugs market with breakthrough GLP-1 innovation.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.strategymrc.com\/blog\/chinas-mazdutide-surpasses-semaglutide\/","og_locale":"en_US","og_type":"article","og_title":"China\u2019s Mazdutide Surpasses Semaglutide | A New Era for the Global Diabetes Drugs Market","og_description":"Discover how China\u2019s Mazdutide outperformed Novo Nordisk\u2019s Semaglutide in clinical trials \u2014 reshaping the $85B global diabetes drugs market with breakthrough GLP-1 innovation.","og_url":"https:\/\/www.strategymrc.com\/blog\/chinas-mazdutide-surpasses-semaglutide\/","og_site_name":"Stratistics MRC","article_published_time":"2025-10-29T10:57:18+00:00","article_modified_time":"2025-10-29T10:57:19+00:00","author":"Akash","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Akash","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.strategymrc.com\/blog\/chinas-mazdutide-surpasses-semaglutide\/#article","isPartOf":{"@id":"https:\/\/www.strategymrc.com\/blog\/chinas-mazdutide-surpasses-semaglutide\/"},"author":{"name":"Akash","@id":"https:\/\/www.strategymrc.com\/blog\/#\/schema\/person\/599a89cba7fe0a22404cf43445567bdf"},"headline":"China\u2019s Mazdutide Surpasses Semaglutide| A New Era for the Global Diabetes Drugs Market","datePublished":"2025-10-29T10:57:18+00:00","dateModified":"2025-10-29T10:57:19+00:00","mainEntityOfPage":{"@id":"https:\/\/www.strategymrc.com\/blog\/chinas-mazdutide-surpasses-semaglutide\/"},"wordCount":626,"publisher":{"@id":"https:\/\/www.strategymrc.com\/blog\/#organization"},"articleSection":["Blog"],"inLanguage":"en"},{"@type":"WebPage","@id":"https:\/\/www.strategymrc.com\/blog\/chinas-mazdutide-surpasses-semaglutide\/","url":"https:\/\/www.strategymrc.com\/blog\/chinas-mazdutide-surpasses-semaglutide\/","name":"China\u2019s Mazdutide Surpasses Semaglutide | A New Era for the Global Diabetes Drugs Market","isPartOf":{"@id":"https:\/\/www.strategymrc.com\/blog\/#website"},"datePublished":"2025-10-29T10:57:18+00:00","dateModified":"2025-10-29T10:57:19+00:00","description":"Discover how China\u2019s Mazdutide outperformed Novo Nordisk\u2019s Semaglutide in clinical trials \u2014 reshaping the $85B global diabetes drugs market with breakthrough GLP-1 innovation.","breadcrumb":{"@id":"https:\/\/www.strategymrc.com\/blog\/chinas-mazdutide-surpasses-semaglutide\/#breadcrumb"},"inLanguage":"en","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.strategymrc.com\/blog\/chinas-mazdutide-surpasses-semaglutide\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.strategymrc.com\/blog\/chinas-mazdutide-surpasses-semaglutide\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.strategymrc.com\/blog\/"},{"@type":"ListItem","position":2,"name":"China\u2019s Mazdutide Surpasses Semaglutide| A New Era for the Global Diabetes Drugs Market"}]},{"@type":"WebSite","@id":"https:\/\/www.strategymrc.com\/blog\/#website","url":"https:\/\/www.strategymrc.com\/blog\/","name":"Stratistics MRC","description":"","publisher":{"@id":"https:\/\/www.strategymrc.com\/blog\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.strategymrc.com\/blog\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en"},{"@type":"Organization","@id":"https:\/\/www.strategymrc.com\/blog\/#organization","name":"Stratistics MRC","url":"https:\/\/www.strategymrc.com\/blog\/","sameAs":[],"logo":{"@type":"ImageObject","inLanguage":"en","@id":"https:\/\/www.strategymrc.com\/blog\/#\/schema\/logo\/image\/","url":"https:\/\/www.strategymrc.com\/blog\/wp-content\/uploads\/2022\/08\/smrc-logo-sm.png","contentUrl":"https:\/\/www.strategymrc.com\/blog\/wp-content\/uploads\/2022\/08\/smrc-logo-sm.png","width":150,"height":38,"caption":"Stratistics MRC"},"image":{"@id":"https:\/\/www.strategymrc.com\/blog\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.strategymrc.com\/blog\/#\/schema\/person\/599a89cba7fe0a22404cf43445567bdf","name":"Akash","image":{"@type":"ImageObject","inLanguage":"en","@id":"https:\/\/www.strategymrc.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/ef8cf3725231b15449bb719267bbb94f?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/ef8cf3725231b15449bb719267bbb94f?s=96&d=mm&r=g","caption":"Akash"},"url":"https:\/\/www.strategymrc.com\/blog\/author\/akash\/"}]}},"_links":{"self":[{"href":"https:\/\/www.strategymrc.com\/blog\/wp-json\/wp\/v2\/posts\/2082"}],"collection":[{"href":"https:\/\/www.strategymrc.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.strategymrc.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.strategymrc.com\/blog\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.strategymrc.com\/blog\/wp-json\/wp\/v2\/comments?post=2082"}],"version-history":[{"count":2,"href":"https:\/\/www.strategymrc.com\/blog\/wp-json\/wp\/v2\/posts\/2082\/revisions"}],"predecessor-version":[{"id":2084,"href":"https:\/\/www.strategymrc.com\/blog\/wp-json\/wp\/v2\/posts\/2082\/revisions\/2084"}],"wp:attachment":[{"href":"https:\/\/www.strategymrc.com\/blog\/wp-json\/wp\/v2\/media?parent=2082"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.strategymrc.com\/blog\/wp-json\/wp\/v2\/categories?post=2082"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.strategymrc.com\/blog\/wp-json\/wp\/v2\/tags?post=2082"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}